Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases.

Miles TJ, Hennessy AJ, Bax B, Brooks G, Brown BS, Brown P, Cailleau N, Chen D, Dabbs S, Davies DT, Esken JM, Giordano I, Hoover JL, Jones GE, Kusalakumari Sukmar SK, Markwell RE, Minthorn EA, Rittenhouse S, Gwynn MN, Pearson ND.

Bioorg Med Chem Lett. 2016 May 15;26(10):2464-2469. doi: 10.1016/j.bmcl.2016.03.106. Epub 2016 Mar 31.

PMID:
27055939
2.

Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.

Chan PF, Srikannathasan V, Huang J, Cui H, Fosberry AP, Gu M, Hann MM, Hibbs M, Homes P, Ingraham K, Pizzollo J, Shen C, Shillings AJ, Spitzfaden CE, Tanner R, Theobald AJ, Stavenger RA, Bax BD, Gwynn MN.

Nat Commun. 2015 Dec 7;6:10048. doi: 10.1038/ncomms10048.

3.

Crystallization and initial crystallographic analysis of covalent DNA-cleavage complexes of Staphyloccocus aureus DNA gyrase with QPT-1, moxifloxacin and etoposide.

Srikannathasan V, Wohlkonig A, Shillings A, Singh O, Chan PF, Huang J, Gwynn MN, Fosberry AP, Homes P, Hibbs M, Theobald AJ, Spitzfaden C, Bax BD.

Acta Crystallogr F Struct Biol Commun. 2015 Oct;71(Pt 10):1242-6. doi: 10.1107/S2053230X15015290. Epub 2015 Sep 23.

4.

Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases.

Miles TJ, Hennessy AJ, Bax B, Brooks G, Brown BS, Brown P, Cailleau N, Chen D, Dabbs S, Davies DT, Esken JM, Giordano I, Hoover JL, Huang J, Jones GE, Sukmar SK, Spitzfaden C, Markwell RE, Minthorn EA, Rittenhouse S, Gwynn MN, Pearson ND.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5437-41. doi: 10.1016/j.bmcl.2013.07.013. Epub 2013 Jul 17.

PMID:
23968823
5.

Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases.

Miles TJ, Axten JM, Barfoot C, Brooks G, Brown P, Chen D, Dabbs S, Davies DT, Downie DL, Eyrisch S, Gallagher T, Giordano I, Gwynn MN, Hennessy A, Hoover J, Huang J, Jones G, Markwell R, Miller WH, Minthorn EA, Rittenhouse S, Seefeld M, Pearson N.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7489-95. doi: 10.1016/j.bmcl.2011.09.117. Epub 2011 Oct 10.

PMID:
22047689
6.

Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases.

Miles TJ, Barfoot C, Brooks G, Brown P, Chen D, Dabbs S, Davies DT, Downie DL, Eyrisch S, Giordano I, Gwynn MN, Hennessy A, Hoover J, Huang J, Jones G, Markwell R, Rittenhouse S, Xiang H, Pearson N.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7483-8. doi: 10.1016/j.bmcl.2011.09.114. Epub 2011 Oct 10.

PMID:
22030032
7.

Challenges of antibacterial discovery revisited.

Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ.

Ann N Y Acad Sci. 2010 Dec;1213:5-19. doi: 10.1111/j.1749-6632.2010.05828.x. Epub 2010 Nov 8. Review.

PMID:
21058956
8.

Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance.

Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD.

Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. doi: 10.1038/nsmb.1892. Epub 2010 Aug 29.

PMID:
20802486
9.

A rapid microtiter plate assay for measuring the effect of compounds on Staphylococcus aureus membrane potential.

Gentry DR, Wilding I, Johnson JM, Chen D, Remlinger K, Richards C, Neill S, Zalacain M, Rittenhouse SF, Gwynn MN.

J Microbiol Methods. 2010 Nov;83(2):254-6. doi: 10.1016/j.mimet.2010.08.012. Epub 2010 Aug 27.

PMID:
20801170
10.

Type IIA topoisomerase inhibition by a new class of antibacterial agents.

Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN.

Nature. 2010 Aug 19;466(7309):935-40. doi: 10.1038/nature09197. Epub 2010 Aug 4.

PMID:
20686482
11.

Susceptibility of Pseudomonas aeruginosa to catechol-substituted cephalosporin is unrelated to the pyochelin-Fe transporter FptA.

Hoegy F, Gwynn MN, Schalk IJ.

Amino Acids. 2010 May;38(5):1627-9. doi: 10.1007/s00726-009-0353-5. Epub 2009 Sep 24.

PMID:
19777323
12.

Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.

Gentry DR, McCloskey L, Gwynn MN, Rittenhouse SF, Scangarella N, Shawar R, Holmes DJ.

Antimicrob Agents Chemother. 2008 Dec;52(12):4507-9. doi: 10.1128/AAC.00915-08. Epub 2008 Oct 6.

13.

Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL.

Nat Rev Drug Discov. 2007 Jan;6(1):29-40. Epub 2006 Dec 8. Review.

PMID:
17159923
14.

Molecular evolution perspectives on intraspecific lateral DNA transfer of topoisomerase and gyrase loci in Streptococcus pneumoniae, with implications for fluoroquinolone resistance development and spread.

Stanhope MJ, Walsh SL, Becker JA, Italia MJ, Ingraham KA, Gwynn MN, Mathie T, Poupard JA, Miller LA, Brown JR, Amrine-Madsen H.

Antimicrob Agents Chemother. 2005 Oct;49(10):4315-26.

15.

Staphylococcus aureus 3-hydroxy-3-methylglutaryl-CoA synthase: crystal structure and mechanism.

Campobasso N, Patel M, Wilding IE, Kallender H, Rosenberg M, Gwynn MN.

J Biol Chem. 2004 Oct 22;279(43):44883-8. Epub 2004 Aug 2.

16.

Genomic approaches to antibacterial discovery.

Payne DJ, Gwynn MN, Holmes DJ, Rosenberg M.

Methods Mol Biol. 2004;266:231-59.

PMID:
15148422
17.

Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus.

Huang J, O'Toole PW, Shen W, Amrine-Madsen H, Jiang X, Lobo N, Palmer LM, Voelker L, Fan F, Gwynn MN, McDevitt D.

Antimicrob Agents Chemother. 2004 Mar;48(3):909-17.

19.

Enterococcus faecalis acetoacetyl-coenzyme A thiolase/3-hydroxy-3-methylglutaryl-coenzyme A reductase, a dual-function protein of isopentenyl diphosphate biosynthesis.

Hedl M, Sutherlin A, Wilding EI, Mazzulla M, McDevitt D, Lane P, Burgner JW 2nd, Lehnbeuter KR, Stauffacher CV, Gwynn MN, Rodwell VW.

J Bacteriol. 2002 Apr;184(8):2116-22.

20.

Essentiality, expression, and characterization of the class II 3-hydroxy-3-methylglutaryl coenzyme A reductase of Staphylococcus aureus.

Wilding EI, Kim DY, Bryant AP, Gwynn MN, Lunsford RD, McDevitt D, Myers JE Jr, Rosenberg M, Sylvester D, Stauffacher CV, Rodwell VW.

J Bacteriol. 2000 Sep;182(18):5147-52.

21.

Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci.

Wilding EI, Brown JR, Bryant AP, Chalker AF, Holmes DJ, Ingraham KA, Iordanescu S, So CY, Rosenberg M, Gwynn MN.

J Bacteriol. 2000 Aug;182(15):4319-27.

22.

Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.

Broskey J, Coleman K, Gwynn MN, McCloskey L, Traini C, Voelker L, Warren R.

J Antimicrob Chemother. 2000 Apr;45 Suppl 1:95-9.

PMID:
10824039
23.

Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics.

Beauregard DA, Williams DH, Gwynn MN, Knowles DJ.

Antimicrob Agents Chemother. 1995 Mar;39(3):781-5.

24.

SB-202742, a novel beta-lactamase inhibitor isolated from Spondias mombin.

Coates NJ, Gilpin ML, Gwynn MN, Lewis DE, Milner PH, Spear SR, Tyler JW.

J Nat Prod. 1994 May;57(5):654-7.

PMID:
8064298
25.
26.
27.
28.

Selection of variants of Gram-negative bacteria with elevated production of type 1 beta-lactamase.

Gwynn MN, Rolinson GN.

J Antimicrob Chemother. 1983 Jun;11(6):577-81.

PMID:
6411674
29.
30.

Bactericidal action of amoxycillin alone and in combination with gentamicin and rifampicin against Brucella melitensis.

Gwynn MN, Rolinson GN.

J Infect. 1980 Mar;2(1):61-5. No abstract available.

PMID:
7185916
31.
32.

Comparative activities of ampicillin, epicillin and amoxycillin in vitro and in vivo.

Basker MJ, Gwynn MN, White AR.

Chemotherapy. 1979;25(3):170-80.

PMID:
256524

Supplemental Content

Loading ...
Support Center